The United Nations Office at Geneva
Multimedia Newsroom
Edited News | WHO , UNOG , UNITED NATIONS
Bi-weekly Press Briefing: Regeneron COVID-19 Treatment - WHO
WHO back Regeneron COVID-19 drug cocktail, but calls for access and reduction on price
The Regeneron antibody-drug cocktail – casirivimab and imdevimab – has been added to the World Health Organization’s (WHO) list of treatments for people with COVID-19, the UN agency said on Friday, before underscoring the need for lower prices and equitable distribution.
“This is a major breakthrough in the care of COVID-19 patients” said Dr Janet Diaz, WHO head of clinical care. “This is our first recommendation for a therapeutic for those patients with mild, moderate disease,” she said, because it reduces “the need for hospitalisation if they are at high risk”.
WHO’s conditional recommendations are for use of the drug combination on patients who were not severely ill but at high risk of being admitted to hospital with COVID-19, or those with severe cases of the disease and no existing antibodies.
“Giving them this additional antibody seems to show an effect. And what effect is that? A reduction in mortality” Dr Diaz told a briefing in Geneva.
The antibody therapy was granted emergency use authorization in the United States November last year after it was used to treat former President Donald Trump when he was admitted to hospital with COVID-19.
The United Kingdom has also approved Regeneron, while it is under review in Europe. The WHO recommendations were largely based on data from a British study of 9,000 patients in June which found that the therapy reduced deaths in hospitalised patients whose own immune systems had failed to produce a response.
“We are taking the information (from the UK study) and generalizing it to other persons,” said Dr Diaz. “We saw there was a benefit we thought was meaningful.” The treatment has been on the market for decades to treat many other diseases, including cancers. It is based on a class of drugs called monoclonal antibodies which mimic natural antibodies produced by the human body to fight off infections.
Swiss drugmaker Roche has been working in partnership with Regeneron, which holds the patent, to produce the antibody treatment. Dr Diaz urged Regeneron to lower the drug’s price and work on equitable distribution worldwide: “We know that the life-saving benefits and the benefits for patients with COVID-19 is significant and requires action.” Dr Diaz added that UNITAID, an international health agency, was negotiating directly with Roche for lower prices and equitable distribution across all parts of the world, “including low and middle-income countries”.
WHO has also been in discussions with the company for a donation and distribution of the drug through UN Children’s Fund UNICEF, following an allocation criteria set by the health agency. “We are working together with the company so we can address these very important issues so we can have equitable access” she said.
In a statement, WHO said in parallel it had “launched a call to manufacturers who may wish to submit their products for pre-qualification, which would allow for a ramping-up of production and therefore greater availability of the treatment and expanded access. ACT-A partners are also working with WHO on an equitable access framework for recommended COVID-19 therapeutics”. On that subject, Dr Diaz added that “there are bottlenecks and we are aware of those. WHO has launched the pre-qualification expression of interest call so that the manufacturing companies can start to submit their dossiers to WHO”.
ends
STORY: Regeneron COVID-19 Treatment - WHO
TRT: 2’18’’
SOURCE: UNTV CH
LANGUAGE: ENGLISH
ASPECT RATIO: 16:19
DATELINE: 24 Sept 2021, GENEVA, Switzerland
SHOTLIST
- Exterior wide shot, United Nations flag alley.
- Wide shot, inside the bi-weekly press conference room, participants.
- SOUNDBITE (English): Dr Janet Diaz, Head of Clinical Care, World Health Organization (WHO): “So this is a major breakthrough in the care of COVID-19 patients, we have expanded our tools to treat patients with covid-19 and this is our first recommendation for a therapeutic for those patients with mild, moderate disease because of the risk of reducing the need for hospitalization if they are at high risk.”
- Medium shot, participant attending the press briefing.
- SOUNDBITE (English): Dr Janet Diaz, Head of Clinical Care, World Health Organization (WHO): “The first recommendation is a conditional recommendation for use in patients who have non severe COVID-19, so those are patients that are mild or moderate and can be seen in the outpatient setting, but it's on the condition that patients are at the higher risk for severe disease. So not for all the patients, but those at the highest risk.”
- Medium shot, participant attending the briefing.
- SOUNDBITE (English): Dr Janet Diaz, Head of Clinical Care, World Health Organization (WHO): “The second recommendation is a conditional recommendation for patients with severe and critical COVID-19, so those are the sicker patients in the hospital on oxygen, on corticosteroids. The condition here is for those patients that are sero-negative. That means on a serology test at that moment, they have not yet mounted their own antibody response. So giving them this additional antibody seems to show an effect. And what effect is that? A reduction in mortality.”
- Wide shot, speakers at podium and briefing broadcast on large-screen TV.
- SOUNDBITE (English): Dr Janet Diaz, Head of Clinical Care, World Health Organization (WHO): “It is true right now there's limited availability and the cost is high for this monoclonal antibody cocktail. However, with this new recommendation, we know that the life-saving benefits and the benefits for patients with COVID-19 is significant and requires action.”
- Medium shot, participant attending the briefing, podium speaker to rear.
- SOUNDBITE (English): Dr Janet Diaz, Head of Clinical Care, World Health Organization (WHO): “At this time, through the ACT aid mechanism UNITAID is negotiating directly with Roche pharmaceutical companies about manufacturing drugs for lower prices, as you have just described, is very important and equitable distribution across all the regions, including low and middle-income countries.”
- Wide shot, briefing room, the three main speakers of the briefing.
- Medium shot, participants in foreground and to rear.
- Wide shot, press briefing room.
Similar Stories
1
1
1
Edited News | OCHA , UNFPA
The UN in Lebanon appealed for an additional $331.5 million on Friday to help 1.4 million people in crisis as already massive needs continue to grow, three months after deadly violence erupted between Hezbollah fighters and Israeli forces.
1
1
1
Edited News | UNIFIL
UN Security Council meets amid rising Israel-Hezbollah tensions in Lebanon.
1
1
1
Edited News | OHCHR , UNOG
At the biweekly press briefing in Geneva, UN Human Rights spokesperson made the following remarks deplored the death in State custody of Brooklyn Rivera in Nicaragua.
1
1
1
Edited News | WHO
Lebanon: Tyre hospital strikes leave patients without critical care – WHO
The UN health agency in Lebanon is verifying reports of strikes on a hospital in the southern city of Tyre on Monday, amid a concerning rise in attacks on healthcare in the country.
2
1
2
Press Conferences , Edited News | WMO
El Niño confirmed, extreme weather events will be more intense, says WMO
The UN urged all countries on Tuesday to bolster early warning systems after confirming the onset of El Niño, warning that the Pacific Ocean-warming phenomenon will bring above-average temperatures “nearly everywhere” and fuel more extreme weather.
1
1
1
Edited News | WHO
‘A disease you get when you care for someone’: on the frontlines of the Ebola crisis with WHO
Two weeks into the latest Ebola outbreak, the World Health Organization (WHO) is estimating that there are 906 suspected cases of Ebola in the Democratic Republic of Congo (DRC), including 223 suspected deaths.
1
1
1
Edited News | OHCHR , UNOG
UN Human Rights Chief Volker Türk on 29 May called for more robust measures by both states and tech companies to make online platforms safer for children, insisting on effective regulation, oversight and accountability. The digital world that connects children to learning, community and creativity also expose them to real risks, to their safety, to their privacy, and to their well-being. Online harms to kids’ safety, privacy, and well-being are not innate or inevitable.
See High Commissioner video: https://media.un.org/unifeed/en/asset/d357/d3579089
1
1
1
Edited News | UNRWA , WHO
Gaza: Life-saving medicines blocked as killing continues, disease gains ground
In Gaza, a dire humanitarian situation marked by continuing violence, rodent infestations and the spread of diseases is being made worse by blockages of essential medical supplies, UN agencies warned on Friday.
1
1
1
Edited News | OHCHR , UNOG
UN Human Rights spokesperson Shabia Mantoo, warned against the continuing trend of involuntary returns of Afghan refugees and asylum-seekers from host countries to Afghanistan, in violation of international human rights and refugee law, at the bi-weekly press briefing in Geneva.
1
1
1
Edited News | IFRC , OHCHR
Lebanon's first responders face high risks amid conflict, with 116 killed since March.
1
1
1
Edited News | WHO
DRC Ebola outbreak: hundreds of suspected cases, no vaccine
A fast-spreading Ebola outbreak in the Democratic Republic of the Congo (DRC) has health workers rushing to stop transmission while the roll out of any potential vaccine is months away, the UN World Health Organization (WHO) said on Tuesday.